Arcus Biosciences (RCUS) Net Income (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Net Income of -$128.0 million for Q1 2026, down 14.29% year-over-year from -$149.3 million in Q1 2025, and down 20.75% quarter-over-quarter from -$106.0 million in Q4 2025.
Powered by 
Analysis
Arcus Biosciences (RCUS) Net Income (2017 - 2026) Analysis & Trends
Arcus Biosciences' Net Income history runs 10 years deep, the most recent figure standing at -$128.0 million for Q1 2026.
- In Q1 2026, Net Income fell 14.29% year-over-year to -$128.0 million; the TTM figure through Mar 2026 stood at -$369.0 million (up 5.63% YoY), while the FY2025 annual figure was -$353.0 million, down 24.73% from the prior year.
- Net Income for Q1 2026 stood at -$128.0 million, down from -$106.0 million in the prior quarter.
- The five-year high for Net Income was -$4.0 million in Q1 2024, with the low at -$135.0 million in Q3 2025.
- The 5-year median for Net Income is -$80.5 million (2023), against an average of -$83.6 million.
- The sharpest annual moves came in 2024 and 2025: Net Income soared 95.0% in 2024, then plunged 2700.0% in 2025.
- Arcus Biosciences' Net Income stood at -$67.0 million in 2022, then dropped by 20.9% to -$81.0 million in 2023, then decreased by 16.05% to -$94.0 million in 2024, then dropped by 12.77% to -$106.0 million in 2025, then slipped by 20.75% to -$128.0 million in 2026.
- Business Quant data shows RCUS's Net Income at -$128.0 million in Q1 2026, -$106.0 million in Q4 2025, and -$135.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -91.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -91.00 Mn |
| Mar 31, 2026 | -128.00 Mn |
| Dec 31, 2025 | -106.00 Mn |
| Sep 30, 2025 | -135.00 Mn |
| Mar 31, 2025 | -112.00 Mn |
| Dec 31, 2024 | -94.00 Mn |
| Sep 30, 2024 | -92.00 Mn |
| Jun 30, 2024 | -93.00 Mn |
| Mar 31, 2024 | -4.00 Mn |
| Dec 31, 2023 | -81.00 Mn |
| Sep 30, 2023 | -71.00 Mn |
| Jun 30, 2023 | -75.00 Mn |
| Mar 31, 2023 | -80.00 Mn |
| Dec 31, 2022 | -67.00 Mn |
| Sep 30, 2022 | -65.00 Mn |
| Jun 30, 2022 | -67.00 Mn |
| Mar 31, 2022 | -68.00 Mn |
| Dec 31, 2021 | 279.54 Mn |
| Sep 30, 2021 | -77.98 Mn |
| Jun 30, 2021 | -75.97 Mn |